Mariner
CAPR icon

Mariner’s Capricor Therapeutics CAPR Stock Holding History

Mariner’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$469K Sell
15,417
-6,033
-28% -$161K ﹤0.01% 2535
2025
Q4 		$619K Buy
21,450
+7,841
+58% +$102K ﹤0.01% 2303
2025
Q3 		$98.1K Buy
+13,609
New +$100K ﹤0.01% 3363

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Mariner's CAPR Position: Q1 2026 in Review

Mariner reduced its Capricor Therapeutics (CAPR) stake by 28% in Q1 2026, selling an estimated $161K and leaving 15,417 shares worth $469K. The position accounts for ﹤0.01% of the portfolio, ranked #2535.

Mariner first reported a position in CAPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $619K in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Mariner held 15,417 shares of Capricor Therapeutics worth $469K as of Q1 2026.
  • Mariner sold 6,033 Capricor Therapeutics shares in Q1 2026, an estimated $161K.
  • Capricor Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2535 holding.
  • Mariner first reported a position in Capricor Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Mariner's Capricor Therapeutics position peaked at $619K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.